Terms: = Prostate cancer AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9
47 results:
1. Network pharmacology and molecular docking to explore the mechanism of Sheng Xue Bao mixture against iron deficiency anemia.
Wang Y; Qinqin H; Wang H; Zhang H; Zhang X; Liu W; Xiang Z; Gu Y
Medicine (Baltimore); 2023 Sep; 102(37):e35012. PubMed ID: 37713882
[TBL] [Abstract] [Full Text] [Related]
2. Genomic alterations related to HPV infection status in a cohort of Chinese prostate cancer patients.
Lang B; Cao C; Zhao X; Wang Y; Cao Y; Zhou X; Zhao T; Wang Y; Liu T; Liang W; Hu Z; Tian X; Zhang J; Yan Y
Eur J Med Res; 2023 Jul; 28(1):239. PubMed ID: 37461056
[TBL] [Abstract] [Full Text] [Related]
3. Network Pharmacology and Molecular Docking Analysis on Molecular Targets and Mechanisms of Bushen Hugu Decoction in the Treatment of Malignant Tumor Bone Metastases.
Sang T; Zhang T; Wang J; Zheng Y
Biomed Res Int; 2022; 2022():2055900. PubMed ID: 36440359
[TBL] [Abstract] [Full Text] [Related]
4. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder cancer.
Gil-Jimenez A; van Dorp J; Contreras-Sanz A; van der Vos K; Vis DJ; Braaf L; Broeks A; Kerkhoven R; van Kessel KEM; Ribal MJ; Alcaraz A; Wessels LFA; Seiler R; Wright JL; Mengual L; Boormans J; van Rhijn BWG; Black PC; van der Heijden MS
Eur Urol; 2023 Apr; 83(4):313-317. PubMed ID: 35965206
[TBL] [Abstract] [Full Text] [Related]
5. A review on the genetic polymorphisms and susceptibility of cancer patients in Bangladesh.
Babu G; Bin Islam S; Khan MA
Mol Biol Rep; 2022 Jul; 49(7):6725-6739. PubMed ID: 35277785
[TBL] [Abstract] [Full Text] [Related]
6. Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive prostate cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.
Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Basch E; Miladinovic B; Lopez-Gitlitz A; Chi KN
J Urol; 2021 Oct; 206(4):914-923. PubMed ID: 34039013
[TBL] [Abstract] [Full Text] [Related]
7. Estimation of [177Lu]PSMA-617 tumor uptake based on voxel-wise 3D Monte Carlo tumor dosimetry in patients with metastasized castration resistant prostate cancer.
Götz TI; Lang EW; Prante O; Cordes M; Kuwert T; Ritt P; Ludwig B; Schmidkonz C
Nuklearmedizin; 2020 Sep; 59(5):365-374. PubMed ID: 32663888
[TBL] [Abstract] [Full Text] [Related]
8. ercc2 Lys751Gln rs13181 and XRCC2 Arg188His rs3218536 Gene Polymorphisms Contribute to Subsceptibility of Colon, Gastric, HCC, Lung And prostate cancer.
Balkan E; Bilici M; Gundogdu B; Aksungur N; Kara A; Yasar E; Dogan H; Ozturk G
J BUON; 2020; 25(1):574-581. PubMed ID: 32277685
[TBL] [Abstract] [Full Text] [Related]
9. Development and validation of a prediction model for identifying men with intermediate- or high-risk prostate cancer for whom bone imaging is unnecessary: a nation-wide population-based study.
Godtman RA; Månsson M; Bratt O; Robinsson D; Johansson E; Stattin P; Kjölhede H
Scand J Urol; 2019 Dec; 53(6):378-384. PubMed ID: 31805808
[No Abstract] [Full Text] [Related]
10. Efficacy and Safety of Non-Steroidal Anti-Androgens in Patients with Metastatic prostate cancer: Meta-Analysis of Randomized Controlled Trials.
Rashid M; Ramesh M; Shamshavali K; Dang A; Patel H; Undela K
Rev Recent Clin Trials; 2020; 15(1):34-47. PubMed ID: 31692438
[TBL] [Abstract] [Full Text] [Related]
11. Total testosterone density predicts high tumor load and disease reclassification of prostate cancer: results in 144 low-risk patients who underwent radical prostatectomy.
Porcaro AB; Tafuri A; Sebben M; Processali T; Pirozzi M; Shakir A; Amigoni N; Rizzetto R; Brunelli M; Migliorini F; Siracusano S; Artibani W
Int Urol Nephrol; 2019 Dec; 51(12):2169-2180. PubMed ID: 31444696
[TBL] [Abstract] [Full Text] [Related]
12. Evolving Role of Genomics in Genitourinary Neoplasms.
Devitt ME; Dreicer R
Acta Med Acad; 2019 Apr; 48(1):68-77. PubMed ID: 31264434
[TBL] [Abstract] [Full Text] [Related]
13. [Mining and discovery for active components of "Coptidis Rhizome-Magnoliae Officinalis Cortex" based on network pharmacology].
Wu HN; Yu GH; Zhao FZ; Jia XB; Feng L; Shi XH
Zhongguo Zhong Yao Za Zhi; 2019 Feb; 44(4):803-810. PubMed ID: 30989895
[TBL] [Abstract] [Full Text] [Related]
14. Association between the ercc2 Asp312Asn polymorphism and risk of cancer.
Xiao F; Pu J; Wen Q; Huang Q; Zhang Q; Huang B; Huang S; Lan A; Zhang Y; Li J; Zhao D; Shen J; Wu H; He Y; Li H; Yang X
Oncotarget; 2017 Jul; 8(29):48488-48506. PubMed ID: 28489582
[TBL] [Abstract] [Full Text] [Related]
15. [Hypofractionated radiation therapy for localized prostate cancer (first experience)].
Vorob'eva TG; Bednyj IV; Drobjazgin EA; Polovnikov ES
Urologiia; 2016 Feb; (1):70-74. PubMed ID: 28247707
[TBL] [Abstract] [Full Text] [Related]
16. Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer.
Zanusso C; Bortolus R; Dreussi E; Polesel J; Montico M; Cecchin E; Gagno S; Rizzolio F; Arcicasa M; Novara G; Toffoli G
Oncotarget; 2017 Apr; 8(14):22863-22875. PubMed ID: 28206966
[TBL] [Abstract] [Full Text] [Related]
17. Polymorphisms in nucleotide excision repair genes and risk of primary prostate cancer in Chinese Han populations.
Wang M; Li Q; Gu C; Zhu Y; Yang Y; Wang J; Jin L; He J; Ye D; Wei Q
Oncotarget; 2017 Apr; 8(15):24362-24371. PubMed ID: 27974699
[TBL] [Abstract] [Full Text] [Related]
18. Social inequalities and cancer: can the European deprivation index predict patients' difficulties in health care access? a pilot study.
Moriceau G; Bourmaud A; Tinquaut F; Oriol M; Jacquin JP; Fournel P; Magné N; Chauvin F
Oncotarget; 2016 Jan; 7(1):1055-65. PubMed ID: 26540571
[TBL] [Abstract] [Full Text] [Related]
19. Single nucleotide polymorphisms in DNA repair genes as risk factors associated to prostate cancer progression.
Henríquez-Hernández LA; Valenciano A; Foro-Arnalot P; Álvarez-Cubero MJ; Cozar JM; Suárez-Novo JF; Castells-Esteve M; Fernández-Gonzalo P; De-Paula-Carranza B; Ferrer M; Guedea F; Sancho-Pardo G; Craven-Bartle J; Ortiz-Gordillo MJ; Cabrera-Roldán P; Herrera-Ramos E; Rodríguez-Gallego C; Rodríguez-Melcón JI; Lara PC
BMC Med Genet; 2014 Dec; 15():143. PubMed ID: 25540025
[TBL] [Abstract] [Full Text] [Related]
20. Common variants of xeroderma pigmentosum genes and prostate cancer risk.
Mirecka A; Paszkowska-Szczur K; Scott RJ; Górski B; van de Wetering T; Wokołorczyk D; Gromowski T; Serrano-Fernandez P; Cybulski C; Kashyap A; Gupta S; Gołąb A; Słojewski M; Sikorski A; Lubiński J; Dębniak T
Gene; 2014 Aug; 546(2):156-61. PubMed ID: 24933002
[TBL] [Abstract] [Full Text] [Related]
[Next]
